



CERTIFICATE OF ANALYSIS




Product Details

Product name:	Anti-Factor IX & Factor X Reference Antibody (Emicizumab)	Lot.No.:	P246742
Target:	F9 / Factor IX, Factor X / FXa	Catalog:	CHBA063
Target Accession:	P00740 & P00742	Concentration :	1 mg/mL
Clonality:	Bispecific	Isotype:	IgG-like
Reactivity:	Human	Molecular Weight (kDa) :	145.62 kDa
Application:	Kinetics (SPR), ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0 Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	Upon receipt, store immediately at -20°C or lower for 24 months. Store aliquots at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.	Purification:	Protein A


Data

MASS




The detected molecular weight of Anti-Factor IX & Factor X Reference Antibody (Emicizumab) is 145.60 kDa.

Purity: SDS-PAGE




Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC



Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) is 100.00%, determined by SEC-HPLC.


ELISA



Emicizumab bound to Factor IX protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Emicizumab bound in human Factor IX Protein-His, and the EC50 was 2.296 nM.

The products are for research use only. Not for use in diagnostic procedures.

ELISA



Emicizumab bound to Factor X protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Emicizumab bound in human Factor X Protein-His, and the EC50 was 2.033 nM.

The products are for research use only. Not for use in diagnostic procedures.